1.
South Med J
; 101(12): 1261-2, 2008 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19005432
RESUMO
Newer biological treatment strategies have been developed in the last decade with some promising outcomes. Their safety, however, has been questioned lately with multiple reports of increased risk for malignancies and infectious complications. These reports render their use suboptimal. We report a 44-year-old woman receiving adalimumab (Humira) for advanced juvenile rheumatoid arthritis who then developed acute myelogenic leukemia.